Today, I’m joined by Shahab Elmi, co-founder & CEO of Cymbiotika.
With 100M+ packets sold in its first six years, Cymbiotika is bringing transparency to the supplement industry with liposomal formulations and rigorous third-party testing.
In this episode, we discuss building a supplement brand focused on efficacy over marketing.
We also cover:
- Liposomal delivery as a differentiator
- Why churn reveals true product efficacy
- Avoiding the wellness DTC race to the bottom
The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities.
Chapters:
(00:00) Introduction
(01:15) Shahab’s background and Cymbiotika’s origin story
(02:00) The problem with the supplement industry
(02:45) Why transparency and testing matter
(04:15) Churn rate as the ultimate success metric
(05:45) Organic celebrity endorsements vs paid sponsorships
(09:00) Liposomal delivery technology explained
(12:30) Manufacturing in-house vs outsourcing
(16:00) The DTC race to the bottom
(18:30) Building trust through radical transparency
(20:30) Competing on efficacy, not marketing spend
(23:00) Taking on industry fraud and fake claims
(24:30) Announcing multiple third-party clinical trials
(26:50) Patent enforcement and liposome validation
(27:35) Product roadmap
(29:25) Conclusion
